CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $198,680.04 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

CRISPR Therapeutics Stock Performance

CRSP opened at $48.29 on Friday. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The business has a 50 day moving average price of $47.15 and a 200 day moving average price of $53.56. The firm has a market cap of $4.10 billion, a P/E ratio of -17.75 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. During the same period in the prior year, the company posted ($0.98) earnings per share. The company’s revenue for the quarter was down 99.3% compared to the same quarter last year. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Integrated Advisors Network LLC increased its position in shares of CRISPR Therapeutics by 6.9% during the 4th quarter. Integrated Advisors Network LLC now owns 7,703 shares of the company’s stock worth $482,000 after purchasing an additional 500 shares in the last quarter. Greenwood Capital Associates LLC increased its holdings in shares of CRISPR Therapeutics by 23.8% during the fourth quarter. Greenwood Capital Associates LLC now owns 6,801 shares of the company’s stock worth $426,000 after buying an additional 1,306 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of CRISPR Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock valued at $99,575,000 after acquiring an additional 51,926 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $270,000. Finally, Nomura Holdings Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $433,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CRSP. Stifel Nicolaus decreased their price objective on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Needham & Company LLC decreased their price objective on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada dropped their target price on CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $75.19.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.